|
| Rank | Title | First author | Publishing year | Journal | Cited times | Citation/year |
|
| 1 | Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Post-Menopausal Osteoporosis | Liberman, Uri A | 1995 | New England Journal of medicine | 1884 | 69.78 (4) |
| 2 | Once-Yearly Zoledronic Acid for Treatment of Post-Menopausal Osteoporosis | Black, DM | 2007 | New England Journal of medicine | 1855 | 123.67 (1) |
| 3 | Effects of Risedronate Treatment on Vertebral and Non-Vertebral Fractures in Women with Post-Menopausal Osteoporosis - A Randomized Controlled Trial | Harris, ST | 1999 | Jama-Journal of the American Medical Association | 1829 | 79.52 (2) |
| 4 | Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Post-Menopausal Osteoporosis | Reginster, JY | 2000 | Osteoporosis International | 1179 | 53.59 (6) |
| 5 | Ten Years’ Experience with Alendronate for Osteoporosis in Post-Menopausal Women | Bone, HG | 2004 | New England Journal of Medicine | 995 | 55.28 (5) |
| 6 | Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis | Saag, Kenneth G | 1998 | New England Journal of Medicine | 913 | 38.04 (11) |
| 7 | Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Post-Menopausal Osteoporosis | Chesnut, CH | 2004 | Journal of Bone and Mineral Research | 891 | 49.5 (7) |
| 8 | Intermittent Cyclical Etidronate Treatment of Post-Menopausal Osteoporosis | Watts, N B | 1990 | The New England Journal of Medicine | 879 | 27.47 (18) |
| 9 | The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Post-Menopausal Osteoporosis | Black, DM | 2003 | New England Journal of Medicine | 866 | 45.58 (9) |
| 10 | Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Post-Menopausal Osteoporosis | Storm, T | 1990 | The New England Journal of Medicine | 846 | 26.44 (19) |
| 11 | Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial | Black, DM | 2000 | Journal of Clinical Endocrinology and Metabolism | 744 | 33.82 (14) |
| 12 | Alendronate for the Treatment of Osteoporosis in Men | Orwoll, E | 2000 | New England Journal of Medicine | 650 | 29.55 (17) |
| 13 | Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis | Adachi, Jonathan D | 1997 | New England Journal of Medicine | 594 | 23.76 (22) |
| 14 | The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis | Finkelstein, JS | 2003 | New England Journal of Medicine | 580 | 30.53 (15) |
| 15 | Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis | Saag, Kenneth G | 2007 | New England Journal of Medicine | 543 | 36.2 (12) |
| 16 | Histomorphometric Assessment of the Long-Term Effects of Alendronate on Bone Quality and Remodeling in Patients with Osteoporosis | Chavassieux, Pascale M | 1997 | Journal of Clinical Investigation | 436 | 17.44 (32) |
| 17 | One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis | Black, DM | 2005 | New England Journal of Medicine | 431 | 25.35 (20) |
| 18 | Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid-Induced Osteoporosis in Men and Women: A Randomized Trial | Reid, DM | 2000 | Journal of Bone and Mineral Research | 408 | 18.55 (28) |
| 19 | Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis | Saag, Kenneth G | 2017 | New England Journal of Medicine | 391 | 78.2 (3) |
| 20 | Therapeutic Equivalence of Alendronate 70 mg Once-Weekly and Alendronate 10 mg Daily in the Treatment of Osteoporosis | Schnitzer, T | 2000 | Aging Clinical and Experimental Research | 370 | 16.82 (33) |
| 21 | The Effect of 3 versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT) | Black, DM | 2012 | Journal of Bone and Mineral Research | 346 | 34.6 (13) |
| 22 | Meta-Analysis of Alendronate for the Treatment of Post-Menopausal Women | Cranney, A | 2002 | Endocrine Reviews | 332 | 16.6 (34) |
| 23 | Prevention of Steroid-Induced Osteoporosis with (3-Amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD | Reid, IR | 1988 | Lancet | 331 | 9.74 (56) |
| 24 | Four-Year Study of Intermittent Cyclic Etidronate Treatment of post-Menopausal Osteoporosis: Three Years of Blinded Therapy Followed by One Year of Open Therapy | Harris, ST | 1993 | The American Journal of Medicine | 324 | 11.17 (50) |
| 25 | Compliance and Persistence with Bisphosphonate Dosing Regimens among Women with Post-Menopausal Osteoporosis | Cramer, JA | 2005 | Current Medical Research and Opinion | 321 | 18.88 (27) |
| 26 | Zoledronic Acid and Risedronate in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (HORIZON): A Multicentre, Double-Blind, Double-Dummy, Randomized Controlled Trial | Reid, David M | 2009 | Lancet | 311 | 23.92 (21) |
| 27 | Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research | Adler, Robert A | 2016 | Journal of Bone and Mineral Research | 295 | 49.17 (8) |
| 28 | Effects of Teriparatide versus Alendronate for Treating Glucocorticoid-Induced Osteoporosis Thirty-Six-Month Results of a Randomized, Double-Blind, Controlled Trial | Saag, Kenneth G | 2009 | Arthritis and Rheumatism | 282 | 21.69 (24) |
| 29 | Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday | McClung, Michael | 2013 | American Journal of Medicine | 274 | 30.44 (16) |
| 30 | Skeletal Benefits of Alendronate: 7-Year Treatment of Post-Menopausal Osteoporotic Women | Tonino, RP | 2000 | Journal of Clinical Endocrinology and Metabolism | 270 | 12.27 (46) |
| 31 | Treatment with Once-Weekly Alendronate 70 mg Compared with Once-Weekly Risedronate 35 mg in Women with Post-Menopausal Osteoporosis: A Randomized Double-Blind Study | Rosen, CJ | 2005 | Journal of Bone and Mineral Research | 268 | 15.76 (37) |
| 32 | Monthly Oral Ibandronate Therapy in Post-Menopausal Osteoporosis: 1-Year Results from the MOBILE Study | Miller, PD | 2005 | Journal of Bone and Mineral Research | 264 | 15.53 (38) |
| 33 | A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] with Alendronate in Post-Menopausal Women with Osteoporosis | Body, JJ | 2002 | Journal of Clinical Endocrinology and Metabolism | 257 | 12.85 (44) |
| 34 | Seven Years of Treatment with Risedronate in Women with Post-Menopausal Osteoporosis | Mellstrom, DD | 2004 | Calcified Tissue International | 245 | 13.61 (41) |
| 35 | Efficacy and Tolerability of Once-Monthly Oral Ibandronate in Post-Menopausal Osteoporosis: 2-Year Results from the MOBILE Study | Reginster, JY | 2006 | Annals of the Rheumatic Diseases | 244 | 15.25 (39) |
| 36 | The Efficacy and Tolerability of Risedronate Once a Week for the Treatment of Post-Menopausal Osteoporosis | Brown, JP | 2002 | Calcified Tissue International | 233 | 11.65 (48) |
| 37 | Larger Increases in Bone Mineral Density during Alendronate Therapy Are Associated with a Lower Risk of New Vertebral Fractures in Women with Post-Menopausal Osteoporosis | Hochberg, MC | 1999 | Arthritis and Rheumatism | 232 | 10.09 (54) |
| 38 | Prevention of Nonvertebral Fractures by Alendronate. A Meta-Analysis. Alendronate Osteoporosis Treatment Study Groups | Karpf, DB | 1997 | JAMA | 232 | 9.28 (60) |
| 39 | Alendronate Prevents Post-Menopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial | Mcclung, Michael | 1998 | Annals of Internal Medicine | 221 | 9.21 (62) |
| 40 | Effects of Intravenous Zoledronic Acid plus Subcutaneous Teriparatide [rhPTH(1–34)] in Postmenopausal Osteoporosis | Cosman, felicia | 2011 | Journal of Bone and Mineral Research | 217 | 19.73 (25) |
| 41 | Meta-Analysis of Risedronate for the Treatment of Post-Menopausal Osteoporosis | Cranney, A | 2002 | Endocrine Reviews | 217 | 10.85 (51) |
| 42 | Intravenous Ibandronate Injections in Post-Menopausal Women with Osteoporosis - One-Year Results from the Dosing Intravenous Administration Study | Delmas, Pierre D | 2006 | Arthritis and Rheumatism | 213 | 13.31 (42) |
| 43 | Elimination and Biochemical Responses to Intravenous Alendronate in Post-Menopausal Osteoporosis | Khan, Sohail A | 1997 | Journal of Bone and Mineral Research | 194 | 7.76 (72) |
| 44 | Continuing Bisphosphonate Treatment for Osteoporosis - for Whom and for How Long? | Black, Dennis M | 2012 | New England Journal of Medicine | 193 | 19.3 (26) |
| 45 | Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis | Boonen, Steven | 2012 | New England Journal of Medicine | 182 | 18.2 (29) |
| 46 | Risedronate Rapidly Reduces the Risk for Nonvertebral Fractures in Women with Post-Menopausal Osteoporosis | Harrington, JT | 2004 | Calcified Tissue International | 180 | 10 (55) |
| 47 | Effect of Three Years of Oral Alendronate Treatment in Post-Menopausal Women with Osteoporosis | Tucci, Joseph R | 1996 | American Journal of Medicine | 178 | 6.85 (77) |
| 48 | Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis | Finkelstein, Joel S | 2010 | Journal of Clinical Endocrinology and Metabolism | 177 | 14.75 (40) |
| 49 | Effects of Teriparatide and Alendronate on Vertebral Strength as Assessed by Finite Element Modeling of QCT Scans in Women with Osteoporosis | Keaveny, Tony M | 2007 | Journal of Bone and Mineral Research | 174 | 11.6 (49) |
| 50 | A Systematic Review and Economic Evaluation of Alendronate, Etidronate, Risedronate, Raloxifene and Teriparatide for the Prevention and Treatment of Post-Menopausal Osteoporosis | Stevenson, M | 2005 | Health Technology Assessment | 174 | 10.24 (53) |
| 51 | Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women | Bone, Henry G | 1997 | Journal of Clinical Endocrinology and Metabolism | 173 | 6.92 (76) |
| 52 | Additive Effects of Raloxifene and Alendronate on Bone Density and Biochemical Markers of Bone Remodeling in Post-Menopausal Women with Osteoporosis | Johnell, O | 2002 | Journal of Clinical Endocrinology and Metabolism | 169 | 8.45 (65) |
| 53 | Effects of Long-Term Risedronate on Bone Quality and Bone Turnover in Women with Post-Menopausal Osteoporosis | Eriksen, EF | 2002 | Bone | 165 | 8.25 (67) |
| 54 | Three Monthly Intravenous Injections of Ibandronate in the Treatment of Post-Menopausal Osteoporosis | Thiebaud, D | 1997 | American Journal of Medicine | 164 | 6.56 (79) |
| 55 | Effects of Teriparatide and Risedronate on New Fractures in Post-Menopausal Women with Severe Osteoporosis (VERO): A Multicentre, Double-Blind, Double-Dummy, Randomized Controlled Trial | Kendler, David L | 2018 | Lancet | 163 | 40.75 (10) |
| 56 | Benefits and Risks of Bisphosphonate Therapy for Osteoporosis | Khosla, Sundeep | 2012 | Journal of Clinical Endocrinology and Metabolism | 162 | 16.2 (36) |
| 57 | Oral Alendronate Induces Progressive Increases in Bone Mass of the Spine, Hip, and Total Body over 3 Years in Post-Menopausal Women with Osteoporosis | Devogelaer, J. P | 1996 | Bone | 161 | 6.19 (82) |
| 58 | Clinical Review: Bisphosphonate Use in Childhood Osteoporosis | Bachrach, Laura K | 2009 | Journal of Clinical Endocrinology and Metabolism | 159 | 12.23 (69) |
| 59 | Two-Year Results of Once-Weekly Administration of Alendronate 70 mg for the Treatment of Post-Menopausal Osteoporosis | Greenspan, SL | 2002 | Journal of Bone and Mineral Research | 159 | 7.95 (47) |
| 60 | Bisphosphonate-Related Osteonecrosis of the Jaw: Position Paper from the Allied Task Force Committee Of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons | Yoneda, Toshiyuki | 2010 | Journal of Bone and Mineral Metabolism | 157 | 13.08 (70) |
| 61 | Significant Differential Effects of Alendronate, Estrogen, or Combination Therapy on the Rate of Bone Loss after Discontinuation of Treatment of Post-Menopausal Osteoporosis - A Randomized, Double-Blind, Placebo-Controlled Trial | Greenspan, SL | 2002 | Annals of Internal Medicine | 157 | 7.85 (43) |
| 62 | Alendronate or Alfacalcidol in Glucocorticoid-Induced Osteoporosis | De nijs, Ron N. J | 2006 | New England Journal of Medicine | 151 | 9.44 (59) |
| 63 | Poor Bisphosphonate Adherence for Treatment of Osteoporosis Increases Fracture Risk: Systematic Review and Meta-Analysis | Imaz, I | 2010 | Osteoporosis International | 150 | 12.5 (45) |
| 64 | Osteonecrosis of the Jaw and Bisphosphonate Treatment for Osteoporosis | Rizzoli, Rene | 2008 | Bone | 149 | 10.64 (52) |
| 65 | Comparison of Teriparatide and Bisphosphonate Treatment to Reduce Pedicle Screw Loosening after Lumbar Spinal Fusion Surgery in Postmenopausal Women with Osteoporosis from a Bone Quality Perspective | Ohtori, Seiji | 2013 | Spine | 148 | 16.44 (35) |
| 66 | Patient Preference for Once-Monthly Ibandronate versus Once-Weekly Alendronate in a Randomized, Open-Label, Crossover Trial: The boniva Alendronate Trial in Osteoporosis (BALTO) | Emkey, R | 2005 | Current Medical Research and Opinion | 147 | 8.65 (64) |
| 67 | Cyclical Etidronate Reverses Bone Loss of the Spine and Proximal Femur in Patients with Established Corticosteroid-Induced Osteoporosis | Struys, Ard | 1995 | American Journal of Medicine | 143 | 5.3 (88) |
| 68 | Addition of Alendronate to Ongoing Hormone Replacement Therapy in the Treatment of Osteoporosis: A Randomized, Controlled Clinical Trial | Lindsay, R | 1999 | Journal of Clinical Endocrinology and Metabolism | 141 | 6.13 (83) |
| 69 | Maintained Improvement in Calcium Balance and Bone Mineral Content in Patients with Osteoporosis Treated with the Bisphosphonate APD. | Valkema, R | 1989 | Bone and Mineral | 141 | 4.27 (99) |
| 70 | Risedronate Preserves Bone Architecture in Post-Menopausal Women with Osteoporosis as Measured by Three-Dimensional Microcomputed Tomography | Borah, B | 2004 | Bone | 139 | 7.72 (73) |
| 71 | Efficacy and Safety of Alendronate for the Treatment of Osteoporosis in Diffuse Connective Tissue Diseases in Children - A Prospective Multicenter Study | Bianchi, ML | 2000 | Arthritis and Rheumatism | 139 | 6.32 (81) |
| 72 | Changes in Bone Histomorphometry after Long-Term Treatment with Intermittent, Cyclic Etidronate for Post-Menopausal Osteoporosis. | Storm, T | 1993 | Journal of Bone and Mineral Research | 139 | 4.79 (92) |
| 73 | Effect of Monitoring Bone Turnover Markers on Persistence with Risedronate Treatment of Post-Menopausal Osteoporosis | Delmas, Pierre D | 2007 | Journal of Clinical Endocrinology and Metabolism | 137 | 9.13 (63) |
| 74 | Biochemical Markers Can Predict the Response in Bone Mass During Alendronate Treatment in Early Post-Menopausal Women | Ravn, P | 1999 | Bone | 137 | 5.96 (86) |
| 75 | Early Responsiveness of Women with Osteoporosis to Teriparatide after Therapy with Alendronate or Risedronate | Miller, Paul D | 2008 | Journal of Clinical Endocrinology and Metabolism | 136 | 9.71 (57) |
| 76 | Insufficiently Dosed Intravenous Ibandronate Injections are Associated with Suboptimal Antifracture Efficacy in Post-Menopausal Osteoporosis | Recker, R | 2004 | Bone | 134 | 7.44 (74) |
| 77 | The Effect on Bone Mass and Bone Markers of Different Doses of Ibandronate: A New Bisphosphonate for Prevention and Treatment of Post-Menopausal Osteoporosis: A 1-Year, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study | Ravn, P | 1996 | Bone | 130 | 5 (90) |
| 78 | The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT) | Black, Dennis M | 2015 | Journal of Bone and Mineral Research | 126 | 18 (30) |
| 79 | Effects of Oral Alendronate in Elderly Patients with Osteoporosis and Mild Primary Hyperparathyroidism | Rossini, M | 2001 | Journal of Bone and Mineral Research | 125 | 5.95 (87) |
| 80 | Continuous Therapy with Pamidronate, a Potent Bisphosphonate, in Post-Menopausal Osteoporosis | Reid, IR | 1994 | The Journal of Clinical Endocrinology and Metabolism | 125 | 4.46 (97) |
| 81 | A Four-Year Randomized Controlled Trial of Hormone Replacement and Bisphosphonate, Alone or in Combination, in Women with post-Menopausal Osteoporosis | Wimalawansa, Sunil J | 1998 | American Journal of Medicine | 123 | 5.13 (89) |
| 82 | Effects of Oral Alendronate and Intranasal Salmon Calcitonin on Bone Mass and Biochemical Markers of Bone Turnover in Post-Menopausal Women with Osteoporosis | Adami, S | 1995 | Bone | 123 | 4.56 (96) |
| 83 | Once-Weekly Risedronate in Men with Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study | Boonen, Steven | 2009 | Journal of Bone and Mineral Research | 120 | 9.23 (61) |
| 84 | Romosozumab (Sclerostin Monoclonal Antibody) versus Teriparatide in Post-Menopausal Women with Osteoporosis Transitioning from Oral Bisphosphonate Therapy: A Randomized, Open-Label, Phase 3 Trial | Langdahl, Bente L | 2017 | Lancet | 118 | 23.6 (23) |
| 85 | Efficacy and Tolerability of Intravenous Ibandronate Injections in Post-Menopausal Osteoporosis: 2-year Results from the DIVA Study | Eisman, John A | 2008 | Journal of Rheumatology | 117 | 8.36 (66) |
| 86 | Ibandronate in Osteoporosis: Preclinical Data and Rationale for Intermittent Dosing | Bauss, F | 2004 | Osteoporosis International | 116 | 6.44 (80) |
| 87 | Intermittent Intravenous Ibandronate Injections Reduce Vertebral Fracture Risk in Corticosteroid-Induced Osteoporosis: Results from a Long-Term Comparative Study | Ringe, JD | 2003 | Osteoporosis International | 116 | 6.11 (84) |
| 88 | Efficacy of Risedronate in Men with Primary and Secondary Osteoporosis: Results of a 1-Year Study | Ringe, JD | 2006 | Rheumatology International | 115 | 7.19 (75) |
| 89 | Efficacy and Safety of a Once-Yearly i.v. Infusion of Zoledronic Acid 5 mg versus a Once-Weekly 70-mg Oral Alendronate in the Treatment of Male Osteoporosis: A Randomized, Multicenter, Double-Blind, Active-Controlled Study | Orwoll, Eric S | 2010 | Journal of Bone and Mineral Research | 114 | 9.5 (58) |
| 90 | Clinic Visits and Hospital Admissions for Care of Acid-Related Upper Gastrointestinal Disorders in Women Using Alendronate for Osteoporosis. | Ettinger, B | 1998 | The American Journal of Managed Care | 112 | 4.67 (95) |
| 91 | A Double-Masked Multicenter Comparative Study between Alendronate and Alfacalcidol in Japanese Patients with Osteoporosis | Shiraki, M | 1999 | Osteoporosis International | 110 | 4.78 (93) |
| 92 | Incidence of Osteonecrosis of the Jaw in Women with Post-Menopausal Osteoporosis in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial | Grbic, John T | 2008 | Journal of the American Dental Association | 109 | 7.79 (71) |
| 93 | Comparison of Weekly Treatment of Post-Menopausal Osteoporosis with Alendronate versus Risedronate over Two Years | Bonnick, Sydney | 2006 | Journal of Clinical Endocrinology and Metabolism | 107 | 6.69 (78) |
| 94 | Cyclical Etidronate in the treatment of Post-Menopausal Osteoporosis: Efficacy and Safety after Seven Years of Treatment | Miller, Paul D | 1997 | American Journal of Medicine | 107 | 4.28 (98) |
| 95 | Denosumab or Zoledronic Acid in Postmenopausal Women with Osteoporosis Previously Treated with Oral Bisphosphonates | Miller, P. D | 2016 | Journal of Clinical Endocrinology and Metabolism | 106 | 17.67 (68) |
| 96 | Evidence-Based Guidelines for the Use of Biochemical Markers of Bone Turnover in the Selection and Monitoring of Bisphosphonate Treatment in Osteoporosis: a Consensus Document of the Belgian Bone Club | Bergmann, P | 2009 | International Journal of Clinical Practice | 106 | 8.15 (31) |
| 97 | Efficacy of Pamidronate for Osteoporosis in Patients with Cystic Fibrosis following Lung Transplantation | Aris, RM | 2000 | American Journal of Respiratory and Critical Care Medicine | 105 | 4.77 (94) |
| 98 | Primary Prevention of Glucocorticoid-Induced Osteoporosis with Intravenous Pamidronate and Calcium: A Prospective Controlled 1-Year Study Comparing a Single Infusion, an Infusion Given Once Every 3 Months, and Calcium Alone | Boutsen, Y | 2001 | Journal of Bone and Mineral Research | 104 | 4.95 (91) |
| 99 | Etidronate Disodium in Post-Menopausal Osteoporosis | Heaney, R P | 1976 | Clinical Pharmacology and Therapeutics | 104 | 2.26 (100) |
| 100 | Alendronate, Vitamin D, and Calcium for the Treatment of Osteopenia/Osteoporosis Associated with HIV Infection | Mondy, K | 2005 | JAIDS (Journal of Acquired Immune Deficiency Syndromes) | 102 | 6 (85) |
|
